At Aiolos Bio, we are dedicated to revolutionizing the treatment landscape for respiratory disease and other immunological disorders. Our goal is to provide patients and caregivers with more efficacious therapies that significantly reduce treatment burden. Our vision is embodied in our current focus – the development of a groundbreaking anti-TSLP therapy with best-in-class potential. We are a San Francisco Bay area-based clinical stage biopharma company with additional operations in London, UK. The Aiolos team is comprised of seasoned drug developers, who have successfully developed and launched products for a range of immune conditions, including asthma, rheumatoid arthritis, IPF, and more. As we grow, we will look to add like-minded individuals to our team - those committed to the goal of providing a meaningful difference in the lives of patients suffering from respiratory illnesses and other immune disorders.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $245M
Founded date: 2023
Investors 3
| Date | Name | Website |
| - | Forbion | forbion.co... |
| 25.10.2023 | Sofinnova ... | sofinnova.... |
| 26.10.2023 | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.10.2023 | Series A | $245M | - |
Mentions in press and media 7
| Date | Title | Description | Source |
| 22.04.2024 | Forbion co-leads $75m Series B Financing in SynOx Therapeuti... | •Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures •Funds will be used for pi... | forbion.co... |
| 18.01.2024 | VectorY appoints Khurem Farooq to Board of Directors | · CEO and Co-Founder of Aiolos Bio and previous CEO of Gyroscope Khurem Farooq joins as independent ... | forbion.co... |
| 12.01.2024 | JPM brings pharma firepower, but services quiet | The JPMorgan Health Care Conference ended with more than $10 billion in deal announcements, setting ... | axios.com/... |
| 25.10.2023 | Aiolos Bio Raises $245M in Series A funding | Aiolos Bio, a San Francisco, CA-based clinical-stage biopharmaceutical company, raised $245M in Seri... | finsmes.co... |
| 24.10.2023 | Aiolos Bio Launches With $245M As Asthma-Focused Funding Acc... | 8 Shares Email Facebook Twitter LinkedIn Venture investors have long been keen backers of startups w... | news.crunc... |
| 24.10.2023 | Forbion co-leads $245 million Series A financing of Aiolos | • Series A financing round co-led by Forbion, Atlas Venture, Bain Capital Life Sciences, and Sofinno... | forbion.co... |
| 24.10.2023 | Aiolos Bio Launches with $245 Million Series A Investment to... | - | sofinnova.... |